Table 2.
Acute kidney injury characteristics and outcomes in 3 most commonly reported immune checkpoint inhibitor–associated glomerular diseases
| Glomerular diseases | IQR or n (%)a |
|---|---|
| Pauci-immune glomerulonephritis and renal vasculitis (n = 12) | |
| Peak SCr, mg/dl (IQR) | 4.75 (4.49–5.80) |
| Time to glomerular disease diagnosis, days (IQR) | 73 (53–102) |
| RRT requirement during AKI, n (%) | 3 (33) |
| ANCA serology positivity, n (%) | 2 (20) |
| Duration of post–biopsy procedure follow-up reported, months (IQR) | 5 (3.25–7.5) |
| AKI outcome, n (%) | |
| Complete recovery | 4 (40) |
| Partial recovery | 5 (50) |
| No recovery/ESKD | 1 (10) |
| Cancer outcome, n (%) | |
| Stable/remission | 4 (50) |
| Death | 4 (50) |
| Podocytopathies (minimal change disease/FSGS; n = 11) | |
| Peak SCr, mg/dl (IQR) | 0.99 (0.76–1.2) |
| Time to glomerular disease diagnosis, days (IQR) | 52 (28–420) |
| RRT requirement during AKI, n (%) | 2 (22) |
| Peak proteinuria, g/day (IQR) | 10.3 (9.0–19.0) |
| Post-treatment proteinuria, g/day (IQR) | 0.29 (0.05–1.97) |
| Duration of post–biopsy procedure follow-up reported, months (IQR) | 5.5 (4.0–10.25) |
| AKI outcome, n (%) | |
| Complete recovery | 2 (29) |
| Partial recovery | 3 (43) |
| No recovery/ESKD | 1 (14) |
| Cancer outcome, n (%) | |
| Stable/remission | 3 (37.5) |
| Progression/death | 5 (62.5) |
| C3 glomerulonephritis (n =5) | |
| Peak SCr, mg/dl (IQR) | 3.13 (2.55–3.48) |
| Time to glomerular disease diagnosis, days (IQR) | 58 (53–68) |
| RRT requirement during AKI, n (%) | 0 (0) |
| Duration of post–biopsy procedure follow-up reported, months (IQR) | 4 (3.25–8.0) |
| Abnormal serum complement level(s), low C3, low C4 = 1, low C3, normal C4 = 1, n (%) | 2 (40) |
| AKI outcome, n (%) | |
| Complete recovery | 1 (25) |
| Partial recovery | 3 (75) |
| No recovery/ESKD | 0 (0) |
| Cancer outcome, n (%) | |
| Stable/remission | 2 (50) |
| Death | 2 (50) |
AKI, acute kidney injury; ANCA, antinuclear cytoplasmic antibody; ESKD, end-stage kidney disease; FSGS, focal segmental glomerulosclerosis; IQR, interquartile range; RRT, renal replacement therapy; SCr, serum creatinine.
Data are shown as median (IQR) for continuous variables and n (%).
a
Percentages for each characteristic are calculated as a proportion of the number of patients with data available.